论文部分内容阅读
放免法测定４８例充血性心力衰竭（ＣＨＦ）患者用开搏通治疗前后血浆精氨酸加压素（ＡＶＰ）及β－内啡肽（β－ＥＰ）含量，同时测定呼吸困难疲劳指数。总外周阻力及心指数。结果表明治疗前患者血浆ＡＶＰ及β－ＥＰ分别较正常人增高１．１及１．２倍，治疗后两者均明显降低，ＡＶＰ降低更明显，接近正常人含量。治疗前、后ＡＶＰ与β－ＥＰ之间存在正相关关系（ｒ＝０．３０３及０．３４９，Ｐ均＜０．０５），ＡＶＰ及β－ＥＰ与临床指标均有良好相关。提示ＣＨＦ者血浆ＡＶＰ及β－ＥＰ含量增高，并与ＣＨＦ疾病严重程度相平行，开搏通对ＣＨＦ的治疗作用可能部分通过改善β－ＥＰ及ＡＶＰ分泌及其相互关系介导。
The levels of plasma arginine vasopressin (AVP) and β-endorphin (β-EP) were measured by radioimmunoassay in 48 patients with congestive heart failure (CHF) before and after treatment with Capecotis, and the fatigue index of dyspnea was measured. Total peripheral resistance and cardiac index. The results showed that before treatment, plasma AVP and β-EP levels were 1.1 and 1.2 times higher than normal, respectively, after treatment, both were significantly lower, AVP decreased more significantly, close to the normal content. Before and after treatment, there was a positive correlation between AVP and β-EP (r = 0.303 and 0.349, P <0.05). AVP and β-EP had a good correlation with clinical parameters. It is suggested that the plasma AVP and β-EP levels in CHF patients are increased and paralleled with the severity of CHF disease. The therapeutic effect of Caifentong on CHF may be partly mediated by improving the secretion of β-EP and AVP and their correlation.